Dapagliflozin effects on cardiometabolic outcomes in patients with an acute heart attack. - DAPA-MI

Study identifier:D169DC00001

ClinicalTrials.gov identifier:NCT04564742

EudraCT identifier:2020-000664-31

CTIS identifier:N/A

Study Complete

Official Title

A Registry-based, Randomised, Double-blind, Placebo-Controlled Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on Cardiometabolic Outcomes in Patients without Diabetes with Acute Myocardial Infarction at Increased Risk for Subsequent Development of Heart Failure

Medical condition

Acute Myocardial Infarction

Phase

Phase 3

Healthy volunteers

No

Study drug

Dapagliflozin, Placebo

Sex

All

Actual Enrollment

4017

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 22 Dec 2020
Primary Completion Date: 05 Jul 2023
Study Completion Date: 05 Jul 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Uppsala Clinical Research Center

Inclusion and exclusion criteria